OPPM
BCRX icon

Opus Point Partners Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Opus Point Partners Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-100,000
Closed -$1.03M – 53
2015
Q4 		$1.03M Buy
+100,000
New +$994K 0.68% 40

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Opus Point Partners Management's BCRX Position: Q1 2016 in Review

Opus Point Partners Management sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2016, closing a stake of 100,000 shares — an estimated $1.03M sold.

Opus Point Partners Management first reported a position in BCRX in Q4 2015 and held it in 1 quarter. The position peaked at $1.03M in Q4 2015. 109 funds tracked by Wall St. Rank hold BCRX as of Q1 2016.

  • Opus Point Partners Management reported no remaining BioCryst Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Opus Point Partners Management sold 100,000 BioCryst Pharmaceuticals shares in Q1 2016, an estimated $1.03M.
  • Opus Point Partners Management first reported a position in BioCryst Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Opus Point Partners Management's BioCryst Pharmaceuticals position peaked at $1.03M in Q4 2015.
  • 109 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2016.

Based on Opus Point Partners Management's 13F filing for Q1 2016, filed 13 May 2016.